Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 10:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bipolar Disorder II Clear all
Terminated Phase 2 Interventional Results available

Clinical Trial of a Nutritional Supplement in Adults With Bipolar Disorder

NCT00109577
View directory record Official record
Conditions
Bipolar Disorder
Interventions
MCN36 (nutritional supplement), Placebo
Drug
Lead sponsor
University of Calgary
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Sep 22, 2026, 10:08 PM EDT
Completed Phase 2 Interventional

To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.

NCT06429722
View directory record Official record
Conditions
Major Depressive Episode Associated With Bipolar II Disorder
Interventions
NMRA-335140 80 mg, Placebo
Drug
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
21
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Garden Grove, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 22, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Results available

Gabapentin for Bipolar & Cannabis Use Disorders

NCT03334721
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder, Cannabis Use Disorder, Substance Use Disorders
Interventions
Gabapentin, Placebo Oral Capsule
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 22, 2026, 10:08 PM EDT
Recruiting Not applicable Interventional

Child Bipolar Network Ketogenic Diet Approach to Bipolar Disorder in Adolescents

NCT06920940
View directory record Official record
Conditions
Bipolar Disorder (BD), Bipolar Disorder NOS, Bipolar Disorder I or II, Bipolar Spectrum Disorder, Adolescents
Interventions
Ketogenic Therapy
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
12 Years to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 22, 2026, 10:08 PM EDT
Withdrawn No phase listed Observational

Neurocardiac Interactions Evaluated by Anatomic and Physiologic MRI Assessment

NCT02962154
View directory record Official record
Conditions
Ischemia, Stress, Mental
Interventions
Coronary CT Angiography, Mood Symptom Scale, Anxiety Symptom Scale, Chronic Stress Inventories, Psychosocial Function Questionnaires, General Health and quality of life questionnaires, Magnetic Resonance Imaging
Radiation · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Sep 22, 2026, 10:08 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Psychiatric Genotype/Phenotype Project Repository

NCT00762866
View directory record Official record
Conditions
Depressive Disorder, Major, Bipolar Disorder, Psychotic Disorders
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
16 Years to 65 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 22, 2026, 10:08 PM EDT
Recruiting Phase 2 Interventional

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality

NCT06706232
View directory record Official record
Conditions
Bipolar II Disorder, Depression, Bipolar, Suicidality
Interventions
Psilocybin, Therapeutic Support
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
25 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 22, 2026, 10:08 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression

NCT02600507
View directory record Official record
Conditions
Bipolar Depression
Interventions
Lumateperone (ITI-007), Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
42
States / cities
Rogers, Arkansas • Cerritos, California • Costa Mesa, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Sep 22, 2026, 10:08 PM EDT
Completed Phase 3 Interventional

Acute Treatment of Bipolar II Depression

NCT00074776
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium, Lamotrigine
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2012 · Synced Sep 22, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Differential Responses to Drugs and Sweet Tastes

NCT03810703
View directory record Official record
Conditions
Bipolar II Disorder
Interventions
Placebo oral capsule, d-amphetamine 10 mg oral capsule, d-amphetamine 20 mg oral capsule
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 19 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 22, 2026, 10:08 PM EDT
Recruiting Phase 4 Interventional

Exercise and Olanzapine-samidorphan

NCT06740890
View directory record Official record
Conditions
Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder I or II, Bipolar Disorder NOS
Interventions
Olanzapine-samidorphan + exercise
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 22, 2026, 10:08 PM EDT
Completed Phase 3 Interventional

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

NCT05658510
View directory record Official record
Conditions
Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
Interventions
BXCL501, Matching Placebo
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
24
States / cities
Bellflower, California • Cerritos, California • Culver City, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 22, 2026, 10:08 PM EDT
Completed Not applicable Interventional Results available

Deep Brain Stimulation for Treatment Resistant Depression

NCT00367003
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Deep Brain Stimulation
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 22, 2026, 10:08 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder

NCT04285515
View directory record Official record
Conditions
Bipolar Depression, Major Depressive Disorder
Interventions
Lumateperone, Placebos
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Garden Grove, California • Oceanside, California • Sherman Oaks, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 22, 2026, 10:08 PM EDT
Not listed Not applicable Interventional

Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar Illness

NCT05705063
View directory record Official record
Conditions
Bipolar Disorder I, Bipolar II Disorder, Bipolar I Disorder, Bipolar Disorder, Bipolar Depression, Bipolar and Related Disorders, Bipolar Disorder, Type 1, Bipolar Disorder, Type 2, Bipolar Disorder, Mixed, Obesity, Metabolic Syndrome, Ketogenic Dieting, Weight Gain, Brain Metabolic Disorder, Psychotropic Agents Causing Adverse Effects in Therapeutic Use
Interventions
LCHF Ketogenic Diet
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 22, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain

NCT00709202
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar I Disorder, Bipolar II, Bipolar NOS(Not Otherwise Specified), Psychotic Disorder Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Betahistine, Placebo Oral Tablet
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 59 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Sep 22, 2026, 10:08 PM EDT
Recruiting Phase 4 Interventional

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

NCT07213466
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1
Interventions
Group Therapy Program, semaglutide, Phentermine-Topiramate, naltrexone and bupropion (combination)
Behavioral · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 22, 2026, 10:08 PM EDT
Completed Not applicable Interventional Results available

A Single Blind Study of Cranial Electrical Stimulation in Bipolar II Disorder

NCT01909011
View directory record Official record
Conditions
Bi-polar II Disorder
Interventions
Active CES, Sham CES
Device
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Sep 22, 2026, 10:08 PM EDT
Completed Phase 2 Interventional

Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression

NCT00322764
View directory record Official record
Conditions
Bipolar Depression
Interventions
Uridine
Drug
Lead sponsor
Repligen Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Timeline
Started 2006
U.S. locations
11
States / cities
Stanford, California • Smyrna, Georgia • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2007 · Synced Sep 22, 2026, 10:08 PM EDT
Completed No phase listed Observational

Bipolar Proteomic Assay Validation Study

NCT02746367
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar I and Bipolar II
Interventions
Diagnostic test (LDT)
Other
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Iowa City, Iowa • Minneapolis, Minnesota • Mason, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Sep 22, 2026, 10:08 PM EDT
Completed Phase 3 Interventional

Bipolar II Depression: Lithium, SSRI, or the Combination

NCT00276965
View directory record Official record
Conditions
Bipolar Disorder, Depression
Interventions
Sertraline, Lithium carbonate
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 65 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
3
States / cities
Los Angeles, California • Palo Alto, California • Mason, Ohio
Source: ClinicalTrials.gov public record
Updated May 9, 2013 · Synced Sep 22, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Results available

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

NCT01731119
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS, Autistic Disorder, Asperger Syndrome, Child Development Disorders, Pervasive, Bipolar I Disorder, Bipolar II Disorder, Mood Disorder NOS, Severe Major Depression With Psychotic Features, Single Episode Major Depression Without Psychotic Symptoms, Severe Mood Disorder With Psychotic Features
Interventions
Latuda©
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Years to 19 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 22, 2026, 10:08 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Ginger.io Behavioral Health Study

NCT02491307
View directory record Official record
Conditions
Anxiety, Depression, Bipolar I Disorder, Bipolar II Disorder
Interventions
Ginger.io Smartphone Application
Other
Lead sponsor
Community Health Center, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
4
States / cities
Meriden, Connecticut • Middletown, Connecticut • New Britain, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 22, 2026, 10:08 PM EDT
Active, not recruiting Not applicable Interventional

Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression

NCT03484494
View directory record Official record
Conditions
Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
Interventions
Low Field Magnetic Stimulation
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 22, 2026, 10:08 PM EDT